Blade Air Mobility Announces Second Quarter 2024 Results

Source: GlobeNewswire
Blade Air Mobility Announces Second Quarter 2024 Results
  • Net loss improved by $0.9 million versus the prior year to $(11.3) million in Q2 2024
  • First Q2 with positive Adjusted EBITDA as a public company
  • Adjusted EBITDA improved by $5.4 million versus the prior year to $1.0 million in Q2 2024
  • Highest quarterly Medical revenue since inception of $38.3 million in Q2 2024, a 6.4% sequential increase versus Q1 2024
  • Highest quarterly Medical Segment Adjusted EBITDA since inception of $5.5 million in Q2 2024, up 82.7% versus the prior year period
  • First Q2 with positive Passenger Segment Adjusted EBITDA as a public company, improved by $2.9 million versus the prior year period

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, "Blade" or the "Company"), today announced financial results for the second quarter ended June 30, 2024.

GAAP FINANCIAL RESULTS
(in thousands except percentages, unaudited)

 Three Months Ended June 30,    Six Months Ended June 30,   
 2024 2023 % Change  2024 2023 % Change 
Revenue$67,945  $60,989  11.4% $119,459  $106,260  12.4%
Cost of revenue$51,591  $50,620  1.9% $92,966  $88,727  4.8%
Software development 971   1,440  (32.6)%  1,641   2,563  (36.0)%
General and administrative 25,136   18,410  36.5%  42,345   34,667  22.1%
Selling and marketing 2,396   2,728  (12.2)%  4,524   5,339  (15.3)%
Total operating expenses$80,094  $73,198  9.4% $141,476  $131,296  7.8%
Loss from operations$(12,149) $(12,209) (0.5)% $(22,017) $(25,036) (12.1)%
Net loss$(11,326) $(12,232) (7.4)% $(15,560) $(22,424) (30.6)%
              
Gross profit$11,336  $5,081  123.1% $17,188  $8,310  106.8%
Gross margin 16.7%  8.3% 840bps  14.4%  7.8% 660bps


 
NON-GAAP(1) FINANCIAL RESULTS
(in thousands except percentages, unaudited)
 
 Three Months Ended June 30,    Six Months Ended June 30,   
 2024 2023 Change  2024 2023 % Change 
Revenue$67,945  $60,989  11.4% $119,459  $106,260  12.4%
Cost of revenue 51,591   50,620  1.9%  92,966   88,727  4.8%
Flight Profit(2) 16,354   10,369  57.7%  26,493   17,533  51.1%
Flight Margin 24.1%  17.0% 707bps  22.2%  16.5% 568bps
Adjusted SG&A 15,834   14,869  6.5%  29,602   29,789  (0.6)%
Depreciation and amortization included in cost of revenue 438   52  NM(3)  521   84  NM(3)
Adjusted EBITDA$958  $(4,448) NM(3) $(2,588) $(12,172) (78.7)%
Adjusted EBITDA as a percentage of Revenue 1.4% (7.3)% NM(3) (2.2)% (11.5)% 929bps
Passenger Adjusted EBITDA$782  $(2,075) NM(3) $(1,869) $(5,130) (63.6)%
Medical Adjusted EBITDA$5,524  $3,023  82.7% $9,933  $4,903  102.6%
Adjusted unallocated corporate expenses and software development$(5,348) $(5,396) (0.9)% $(10,652) $(11,945) (10.8)%

(1) See "Use of Non-GAAP Financial Measures" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.
(2) Includes $438 and $52 of depreciation and amortization for owned aircraft and vehicles in the three months ended June 30, 2024 and 2023, respectively and $521 and $84 in the six months ended June 30, 2024 and 2023, respectively.
(3) Not meaningful.

"This quarter marks Blade’s first Adjusted EBITDA positive Q2 as a public company with both the Medical and Passenger segments enjoying strong performance and contributing positive Segment Adjusted EBITDA in the quarter," said Rob Wiesenthal, Blade's Chief Executive Officer. "We are also pleased to see continued sequential growth in Medical as well as increasing adoption of Blade's ground and organ placement offerings. We've exited certain Passenger routes that didn't meet our return thresholds and we remain relentless in our pursuit of profitability in core markets that are showing growth by improving customer acquisition globally, including by launching a new codeshare with Emirates to and from Monaco, by opening two new terminals at Nice Airport and by opening a new heliport in Atlantic City at Ocean Casino."

"We continued our drive towards full-year profitability in the Passenger Segment this quarter, posting our first ever Q2 with positive Passenger Segment Adjusted EBITDA, a $2.9 million improvement versus the prior year period," said Will Heyburn, Chief Financial Officer. "As part of this effort, we restructured our Canadian operations to eliminate further losses and lay the groundwork for our ultimate exit from the Canadian market within the next year. We simply did not see a near-term path to profitability using conventional rotorcraft, however, we remain enthusiastic about the long-term opportunity for Electric Vertical Aircraft in Western Canada and have structured our departure to maintain multiple paths to re-launch Canadian operations in the future, following the introduction of electric vertical aircraft."

"During the quarter, we closed on seven of the eight previously announced jet aircraft acquisitions and we’re encouraged by both the value these aircraft provide to our customers and the initial financial performance of the fleet to date, generating a return on invested capital above 30%," said Melissa Tomkiel, Blade's President. "While we continue to believe that the vast majority of our flying will remain with third-party owned and operated aircraft, we see an opportunity to further improve our customer value proposition while generating strong returns by expanding our fleet of owned aircraft."

Second Quarter Ended June 30, 2024 Financial Highlights

  • Total revenue increased 11.4% to $67.9 million in the current quarter versus $61.0 million in the prior year period. Excluding the impact of discontinuing our BladeOne scheduled by-the-seat jet service between New York and South Florida and the temporary support of a large hospital customer in the year ago period, total revenue increased 17.5% year-over-year.
  • Flight Profit(1) increased 57.7% to $16.4 million in the current quarter versus $10.4 million in the prior year period, driven by strong growth in both the Medical and Passenger segments.
  • Flight Margin(1) improved to 24.1% in the current quarter from 17.0% in the prior year period, driven by strong performance of our owned aircraft fleet, growth in ground revenue and improved pricing in the Medical segment, coupled with improved profitability in our New York Airport transfer product, Europe and Jet Charter in the Passenger segment.
  • Medical revenue increased 11.5% to $38.3 million in the current quarter versus $34.4 million in the prior year period. Medical revenue increased 6.4% sequentially versus Q1 2024. Excluding the impact of our temporary support of a large hospital customer in the prior year period, Medical revenue increased 19.0% year-over-year driven by growth in both block hours flown and revenue per block hour.
  • Short Distance revenue increased 9.0% to $20.9 million in the current quarter versus $19.2 million in the prior year period. The increase was primarily driven by our New York Airport transfer product and growth in Europe.
  • Jet and Other revenue increased 17.4% to $8.7 million in the current quarter versus $7.4 million in the prior year period driven by growth in Jet Charter and non-flight revenue, partially offset by the discontinuation of our BladeOne seasonal by-the-seat jet service between New York and South Florida.
  • Net loss decreased 7.4% to $(11.3) million in the current quarter versus $(12.2) million in the prior year period and improved as a percentage of revenue to (16.7)% in the current quarter from (20.1)% in the prior year period.
  • Adjusted EBITDA(1) improved by $5.4 million year-over-year to $1.0 million in the current quarter versus $(4.4) million in the prior year period, primarily due to an 82.7% increase in Medical Segment Adjusted EBITDA to $5.5 million in the current quarter, and a $2.9 million improvement in Passenger Segment Adjusted EBITDA to $0.8 million. Adjusted Unallocated Corporate Expenses and Software Development decreased (0.9)% versus the prior year period.
  • Capital expenditures of $16.9 million were driven primarily by the $14.6 million purchase of aircraft in the Medical segment.
  • Repurchased 80,102 shares for $0.2 million during the quarter. In addition, we changed our Restricted Stock Unit tax withholding method to “withhold-to-cover” from “sell-to-cover” during the quarter, deploying approximately $1.0 million of balance sheet cash to retire 332,212 shares.
  • Ended Q2 2024 with $142.0 million in cash and short term investments.

Business Highlights and Recent Updates

  • In mid July, Blade opened two new private passenger lounges in terminals 1 and 2 at Nice Côte d'Azur Airport. These lounges enhance the Blade passenger experience by providing a place to relax, enjoy food and refreshments and access free Wi-Fi before the flight. 
  • Blade opened a new rooftop helipad at the Ocean Casino Resort in Atlantic City, NJ and announced a partnership with the resort to offer scheduled service in the summer months.
  • Blade announced a global codeshare agreement with Emirates that enables passengers to fly seamlessly between Dubai and Monaco. When Emirates passengers fly Blade back from Monaco, checked luggage will flow to the final destination and upon arrival at Nice Airport, passengers will be escorted to the helipad-side security clearance for security and customs and driven directly to their gate, bypassing in-terminal congestion and public security queues.
  • During Q2 2024, we closed on seven of the eight aircraft acquisitions that we announced earlier this year and expect to close on the eighth aircraft during Q3 2024.
  • We amended the agreement with our partner in Canada during Q2 2024 to eliminate further losses in 2024 and lay the groundwork for Blade's ultimate exit within the next year.

Financial Outlook(2)

The Company is reaffirming its guidance. For the full year 2024, we expect:

  • Revenue of $240 million to $250 million
  • Positive Adjusted EBITDA

For the full year 2025, we expect:

  • Double-digit year-over-year revenue growth
  • Double-digit Adjusted EBITDA

(1) See "Use of Non-GAAP Financial Measures" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.
(2) We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

Conference Call

The Company will conduct a conference call starting at 4:30 p.m. ET on Wednesday August 7, 2024 to discuss the results for the second quarter ended June 30, 2024.

A live audio-only webcast of the call may be accessed from the Investor Relations section of the Company’s website at https://ir.blade.com/. An archived replay of the call will be available on the Investor Relations section of the Company's website for one year.

Use of Non-GAAP Financial Information
Blade believes that the non-GAAP measures discussed below, viewed in addition to and not in lieu of our reported U.S. Generally Accepted Accounting Principles ("GAAP") results, provide useful information to investors by providing a more focused measure of operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. Adjusted EBITDA, Adjusted Unallocated Corporate Expenses, SG&A, Adjusted SG&A, Flight Profit, Flight Margin and Free Cash Flow have been reconciled to the nearest GAAP measure in the tables within this press release.

Adjusted EBITDA – Blade reports Adjusted EBITDA, which is a non-GAAP financial measure. Blade defines Adjusted EBITDA as net loss adjusted to exclude depreciation and amortization, stock-based compensation, change in fair value of warrant liabilities, interest income and expense, income tax, realized gains and losses on short-term investments, impairment of intangible assets and certain other non-recurring items that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods. 

Adjusted Unallocated Corporate Expenses – Blade defines Adjusted Unallocated Corporate Expenses as expenses that cannot be allocated to either of our reporting segments (Passenger and Medical) and therefore attributable to our Corporate expenses and software development, less non-cash items and certain other non-recurring items that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods.

SG&A and Adjusted SG&A – Blade defines SG&A as total operating expenses excluding cost of revenue. Blade defines Adjusted SG&A as total operating expenses excluding cost of revenue and excluding non-cash items and certain other non-recurring items that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods.

Flight Profit and Flight Margin – Blade defines Flight Profit as revenue less cost of revenue. Cost of revenue consists of flight costs paid to operators of aircraft and vehicles, landing fees, depreciation of aircraft and vehicles, ROU asset amortization, internal costs incurred in generating organ ground transportation revenue using the Company’s owned vehicles and costs of operating our owned aircraft including fuel, management fees paid to the operator, maintenance costs and pilot salaries. Blade defines Flight Margin for a period as Flight Profit for the period divided by revenue for the same period. Blade believes that Flight Profit and Flight Margin provide an important measure of the profitability of the Company's flight and ground operations, as they focus solely on the non discretionary direct variable costs associated with those operations.

Free Cash Flow – Blade defines Free Cash Flow as net cash provided by / (used in) operating activities less capital expenditures and capitalized software development costs. 

Financial Results

 
BLADE AIR MOBILITY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data, unaudited)
 
 June 30,
2024
 December 31,
2023
Assets   
Current assets:   
Cash and cash equivalents$26,308  $27,873 
Restricted cash 2,058   1,148 
Accounts receivable, net of allowance of $278 and $98 at June 30, 2024 and December 31, 2023, respectively 27,723   21,005 
Short-term investments 115,643   138,264 
Prepaid expenses and other current assets 11,180   17,971 
Total current assets 182,912   206,261 
    
Non-current assets:   
Property and equipment, net 22,093   2,899 
Intangible assets, net 13,701   20,519 
Goodwill 39,574   40,373 
Operating right-of-use asset 21,123   23,484 
Other non-current assets 928   1,402 
Total assets$280,331  $294,938 
    
Liabilities and Stockholders' Equity   
Current liabilities:   
Accounts payable and accrued expenses$16,875  $23,859 
Deferred revenue 9,266   6,845 
Operating lease liability, current 4,145   4,787 
Total current liabilities 30,286   35,491 
    
Non-current liabilities:   
Warrant liability 2,393   4,958 
Operating lease liability, long-term 17,864   19,738 
Deferred tax liability 402   451 
Total liabilities 50,945   60,638 
    
Stockholders' Equity   
Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively     
Common stock, $0.0001 par value; 400,000,000 authorized; 77,934,085 and 75,131,425 shares issued at June 30, 2024 and December 31, 2023, respectively 7   7 
Additional paid in capital 401,753   390,083 
Accumulated other comprehensive income 2,777   3,964 
Accumulated deficit (175,151)  (159,754)
Total stockholders' equity 229,386   234,300 
    
Total Liabilities and Stockholders' Equity$280,331  $294,938 


 
BLADE AIR MOBILITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data, unaudited)
 
 Three Months Ended June 30,Six Months Ended June 30,
 2024 2023 2024 2023
Revenue$67,945  $60,989  $119,459  $106,260 
        
Operating expenses       
Cost of revenue 51,591   50,620   92,966   88,727 
Software development 971   1,440   1,641   2,563 
General and administrative 25,136   18,410   42,345   34,667 
Selling and marketing 2,396   2,728   4,524   5,339 
Total operating expenses 80,094   73,198   141,476   131,296 
        
Loss from operations (12,149)  (12,209)  (22,017)  (25,036)
        
Other non-operating income (expense)       
Interest income 1,788   2,077   3,860   4,031 
Change in fair value of warrant liabilities (913)  (2,462)  2,565   (1,896)
Realized loss from sales of short-term investments    (14)     (95)
Total other non-operating income (expense) 875   (399)  6,425   2,040 
        
Loss before income taxes (11,274)  (12,608)  (15,592)  (22,996)
        
Income tax expense (benefit) 52   (376)  (32)  (572)
        
Net loss$(11,326) $(12,232) $(15,560) $(22,424)
        
Net loss per share:       
Basic$(0.15) $(0.17) $(0.20) $(0.31)
Diluted$(0.15) $(0.17) $(0.20) $(0.31)
Weighted-average number of shares outstanding:       
Basic 77,603,604   73,169,003   76,700,008   72,584,138 
Diluted 77,603,604   73,169,003   76,700,008   72,584,138 


 
BLADE AIR MOBILITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)
 
 Three Months Ended June 30,Six Months Ended June 30,
 2024 2023 2024 2023
Cash Flows From Operating Activities:       
Net loss$(11,326) $(12,232) $(15,560) $(22,424)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:       
Depreciation and amortization 1,559   1,810   3,153   3,462 
Stock-based compensation 5,647   2,797   9,965   6,018 
Change in fair value of warrant liabilities 913   2,462   (2,565)  1,896 
Excess of lease liability over operating right-of-use assets (123)     (123)   
Gain on lease modification (6)     (53)   
Realized loss from sales of short-term investments    14      95 
Realized foreign exchange loss 1      4   5 
Accretion of interest income on held-to-maturity securities (816)  (1,638)  (2,297)  (3,024)
Deferred tax expense (benefit) 52   (376)  (32)  (572)
Impairment of intangible assets 5,759      5,759    
Bad debt expense 171      202    
Changes in operating assets and liabilities:       
Prepaid expenses and other current assets 6,374   (1,004)  5,958   (2,625)
Accounts receivable (4,358)  (6,045)  (6,967)  (11,630)
Other non-current assets 510   18   466   (24)
Operating right-of-use assets/lease liabilities 66   300   39   377 
Accounts payable and accrued expenses 2,712   3,470   (7,525)  87 
Deferred revenue 1,294   2,227   2,454   3,307 
Net cash provided by / (used in) operating activities 8,429   (8,197)  (7,122)  (25,052)
        
Cash Flows From Investing Activities:       
Capitalized software development costs (745)     (1,056)   
Purchase of property and equipment (16,163)  (744)  (16,979)  (1,390)
Purchase of short-term investments    (14)     (135)
Proceeds from sales of short-term investments    4,532      20,532 
Purchase of held-to-maturity investments       (77,051)  (130,145)
Proceeds from maturities of held-to-maturity investments       102,740   131,187 
Net cash (used in) / provided by investing activities (16,908)  3,774   7,654   20,049 
        
Cash Flows From Financing Activities:       
Proceeds from the exercise of common stock options 22      113   54 
Taxes paid related to net share settlement of equity awards (986)  (20)  (1,023)  (101)
Repurchase and retirement of common stock (244)     (244)   
Net cash used in financing activities (1,208)  (20)  (1,154)  (47)
        
Effect of foreign exchange rate changes on cash balances (7)  17   (33)  20 
Net decrease in cash and cash equivalents and restricted cash (9,694)  (4,426)  (655)  (5,030)
Cash and cash equivalents and restricted cash - beginning 38,060   43,819   29,021   44,423 
Cash and cash equivalents and restricted cash - ending$28,366  $39,393  $28,366  $39,393 
        
Reconciliation to the unaudited interim condensed consolidated balance sheets       
Cash and cash equivalents$26,308  $37,348  $26,308  $37,348 
Restricted cash 2,058   2,045   2,058   2,045 
Total cash, cash equivalents and restricted cash$28,366  $39,393  $28,366  $39,393 
        
Non-cash investing and financing activities       
New leases under ASC 842 entered into during the period(1)$3,777  $146  $6,358  $7,312 
Common stock issued for settlement of earn-out(1)       3,022   1,785 
Purchases of PPE and capitalized software in accounts payable and accrued expenses 3,348      3,633    
Derecognition of ROU assets (6,367)     (6,367)   
Derecognition of lease liabilities 6,367      6,367    

(1) Prior year amounts have been updated to conform to current period presentation.

Key Metrics and Non-GAAP Financial Information

 
DISAGGREGATED REVENUE BY PRODUCT LINE
(in thousands, unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Passenger segment        
Short Distance$20,908 $19,184 $30,718 $29,609
Jet and Other 8,696  7,406  14,374  15,485
Total$29,604 $26,590 $45,092 $45,094
        
Medical segment       
MediMobility Organ Transport$38,341 $34,399  74,367  61,166
Total$38,341 $34,399 $74,367 $61,166
        
Total Revenue$67,945 $60,989 $119,459 $106,260


 
SEGMENT INFORMATION:  REVENUE, FLIGHT PROFIT, FLIGHT MARGIN, ADJUSTED EBITDA WITH RECONCILIATION TO TOTAL ADJUSTED EBITDA
(in thousands except percentages, unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Passenger$29,604  $26,590  $45,092  $45,094 
Medical 38,341   34,399   74,367   61,166 
Total Revenue$67,945  $60,989  $119,459  $106,260 
        
Passenger$7,317  $4,642  $9,426  $7,454 
Medical 9,037   5,727   17,067   10,079 
Total Flight Profit(1)$16,354  $10,369  $26,493  $17,533 
        
Passenger 24.7%  17.5%  20.9%  16.5%
Medical 23.6%  16.6%  22.9%  16.5%
Total Flight Margin 24.1%  17.0%  22.2%  16.5%
        
Passenger$782  $(2,075) $(1,869) $(5,130)
Medical 5,524   3,023   9,933   4,903 
Adjusted unallocated corporate expenses and software development (5,348)  (5,396)  (10,652)  (11,945)
Total Adjusted EBITDA$958  $(4,448) $(2,588) $(12,172)

(1) Includes $438 and $52 of depreciation and amortization for owned aircraft and vehicles in the three months ended June 30, 2024 and 2023, respectively and $521 and $84 in the six months ended June 30, 2024 and 2023, respectively.

 
SEATS FLOWN - ALL PASSENGER FLIGHTS
(unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Seats flown – all passenger flights44,037 41,637 71,745 70,187


 
REVENUE, FLIGHT PROFIT, FLIGHT MARGIN, ADJUSTED SG&A, ADJUSTED EBITDA
(in thousands except percentages, unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Revenue$67,945  $60,989  $119,459  $106,260 
Flight Profit(1) 16,354   10,369   26,493   17,533 
Flight Margin 24.1%  17.0%  22.2%  16.5%
Adjusted SG&A 15,834   14,869   29,602   29,789 
Adjusted SG&A as a percentage of revenue 23.3%  24.4%  24.8%  28.0%
Depreciation and amortization included in cost of revenue 438   52   521   84 
Adjusted EBITDA$958  $(4,448) $(2,588) $(12,172)
Adjusted EBITDA as a percentage of revenue 1.4% (7.3)% (2.2)% (11.5)%

(1) Includes $438 and $52 of depreciation and amortization for owned aircraft and vehicles in the three months ended June 30, 2024 and 2023, respectively and $521 and $84 in the six months ended June 30, 2024 and 2023, respectively.


 
RECONCILIATION OF REVENUE LESS COST OF REVENUE TO FLIGHT PROFIT AND GROSS PROFIT
(in thousands except percentages, unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Revenue$67,945  $60,989  $119,459  $106,260 
Less:       
Cost of revenue(1) 51,591   50,620   92,966   88,727 
Depreciation and amortization 971   1,644   2,211   3,115 
Stock-based compensation 35   40   113   80 
Other(2) 4,012   3,604   6,981   6,028 
Gross Profit$11,336  $5,081  $17,188  $8,310 
Gross Margin 16.7%  8.3%  14.4%  7.8%
        
Gross Profit$11,336  $5,081  $17,188  $8,310 
Reconciling items:       
Depreciation and amortization 971   1,644   2,211   3,115 
Stock-based compensation 35   40   113   80 
Other(2) 4,012   3,604   6,981   6,028 
Flight Profit$16,354  $10,369  $26,493  $17,533 
Flight Margin 24.1%  17.0%  22.2%  16.5%

(1) Cost of revenue consists of flight costs paid to operators of aircraft and vehicles, landing fees, depreciation of aircraft and vehicles, ROU asset amortization, internal costs incurred in generating organ ground transportation revenue using the Company's owned vehicles and costs of operating our owned aircraft including fuel, management fees paid to the operator, maintenance costs and pilot salaries.

(2) Other costs include credit card processing fees, staff costs, commercial costs and establishment costs.

 
RECONCILIATION OF TOTAL OPERATING EXPENSES TO ADJUSTED SG&A
(in thousands except percentages, unaudited)
 
 Three Months Ended June 30,Six Months Ended June 30,
 2024 2023 2024 2023
Revenue$67,945  $60,989  $119,459  $106,260 
        
Total operating expenses 80,094   73,198   141,476   131,296 
Subtract:       
Cost of revenue 51,591   50,620   92,966   88,727 
SG&A$28,503  $22,578  $48,510  $42,569 
SG&A as percentage of Revenue 42.0%  37.0%  40.6%  40.1%
Adjustments to reconcile SG&A to Adjusted SG&A       
Subtract:       
Depreciation and amortization included in SG&A 1,121   1,758   2,632   3,378 
Stock-based compensation 5,546   2,797   10,089   6,018 
Legal and regulatory advocacy fees(1)(2) 139      262   423 
Executive severance costs    119      265 
SOX readiness costs 82   35   82   35 
Contingent consideration compensation (earn-out)(3)    3,000      2,661 
M&A transaction costs 22      84    
Impairment of intangible assets 5,759      5,759  $ 
Adjusted SG&A$15,834  $14,869  $29,602  $29,789 
Adjusted SG&A as percentage of Revenue 23.3%  24.4%  24.8%  28.0%

(1) For the six months ended June 30, 2024, represents legal advocacy fees related to the Drulias lawsuit that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business.
(2) For the six months ended June 30, 2023, represents certain legal and regulatory advocacy fees for certain proposed restrictions at East Hampton Airport and potential operational restrictions on large jet aircraft at Westchester Airport, that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business.
(3) Trinity’s contingent consideration, 2023 was the last year subject to an earn-out payment.

 
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(in thousands except percentages, unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Net loss$(11,326) $(12,232) $(15,560) $(22,424)
        
Depreciation and amortization 1,559   1,810   3,153   3,462 
Stock-based compensation 5,546   2,797   10,089   6,018 
Change in fair value of warrant liabilities 913   2,462   (2,565)  1,896 
Realized loss from sales of short-term investments    14      95 
Interest income (1,788)  (2,077)  (3,860)  (4,031)
Income tax expense (benefit) 52   (376)  (32)  (572)
Legal and regulatory advocacy fees(1)(2) 139      262   423 
Executive severance costs    119      265 
SOX readiness costs 82   35   82   35 
Contingent consideration compensation (earn-out)(3)    3,000      2,661 
M&A transaction costs 22      84    
Impairment of intangible assets 5,759      5,759    
Adjusted EBITDA$958  $(4,448) $(2,588) $(12,172)
Revenue$67,945  $60,989  $119,459  $106,260 
Adjusted EBITDA as a percentage of Revenue 1.4% (7.3)% (2.2)% (11.5)%

(1) For the six months ended June 30, 2024, represents legal advocacy fees related to the Drulias lawsuit that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business.
(2) For the six months ended June 30, 2023, represents certain legal and regulatory advocacy fees for certain proposed restrictions at East Hampton Airport and potential operational restrictions on large jet aircraft at Westchester Airport, that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business.
(3) Trinity’s contingent consideration, 2023 was the last year subject to an earn-out payment.

 
RECONCILIATION OF NET CASH PROVIDED BY / (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW
(in thousands, unaudited)
 
 Three Months Ended June 30, Six Months Ended June 30,
 2024 2023 2024 2023
Net cash provided by / (used in) operating activities$8,429  $(8,197) $(7,122) $(25,052)
Capitalized software development costs (745)     (1,056)   
Purchase of property and equipment (16,163)  (744)  (16,979)  (1,390)
Free Cash Flow$(8,479) $(8,941) $(25,157) $(26,442)


 
LAST TWELVE MONTHS DISAGGREGATED REVENUE BY PRODUCT LINE
(in thousands, unaudited)
 
    Three Months Ended
  Last Twelve
Months
 June 30,
2024
 March 31,
2024
 December 31,
2023
 September 30,
2023
Product Line:          
Short Distance $71,809 $20,908 $9,810 $10,703 $30,388
Jet and Other  26,765  8,696  5,678  4,784  7,607
MediMobility Organ Transport  139,805  38,341  36,026  31,991  33,447
Total Revenue $238,379 $67,945 $51,514 $47,478 $71,442
                

About Blade Air Mobility

Blade Air Mobility provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe. Based in New York City, Blade's asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft (“EVA” or “eVTOL”), enabling lower cost air mobility that is both quiet and emission-free. 

For more information, visit www.blade.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as "will", “anticipate,” “believe,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future,” "target," and “project” and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to Blade’s future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning Blade’s future financial and operating performance (including the discussion of 2024 and 2025 financial outlook and guidance), the composition and performance of its fleet, results of operations, industry environment and growth opportunities, new product lines and partnerships, and the development and adoption of EVA technology. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Blade’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: our continued incurrence of significant losses; failure of the markets for our offerings to grow as expected, or at all; our ability to effectively market and sell air transportation as a substitute for conventional methods of transportation; reliance on certain customers in our Passenger segment revenue; the inability or unavailability to use or take advantage of the shift, or lack thereof, to EVA technology; our ability to successfully enter new markets and launch new routes and services; any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving our third-party operators; any change to the ownership of our aircraft and the challenges related thereto; the effects of competition; harm to our reputation and brand; our ability to provide high-quality customer support; our ability to maintain a high daily aircraft usage rate; changes in consumer preferences, discretionary spending and other economic conditions; impact of natural disasters, outbreaks and pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions or other circumstances on metropolitan areas and airports where we have geographic concentration; the effects of climate change, including potential increased impacts of severe weather and regulatory activity; the availability of aircraft fuel; our ability to address system failures, defects, errors, or vulnerabilities in our website, applications, backend systems or other technology systems or those of third-party technology providers; interruptions or security breaches of our information technology systems; our placements within mobile applications; our ability to protect our intellectual property rights; our use of open source software; our ability to expand and maintain our infrastructure network; our ability to access additional funding; the increase of costs and risks associated with international expansion; our ability to identify, complete and successfully integrate future acquisitions; our ability to manage our growth; increases in insurance costs or reductions in insurance coverage; the loss of key members of our management team; our ability to maintain our company culture; our reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations; effects of fluctuating financial results; our reliance on third-party operators; the availability of third-party operators; disruptions to third-party operators; increases in insurance costs or reductions in insurance coverage for our third-party aircraft operators; the possibility that our third-party aircraft operators may illegally, improperly or otherwise inappropriately operate our branded aircraft; our reliance on third-party web service providers; changes in our regulatory environment; risks and impact of any litigation we may be subject to; regulatory obstacles in local governments; the expansion of domestic and foreign privacy and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses or maintain internal controls over financial reporting; our ability to maintain effective internal controls and disclosure controls; changes in the fair value of our warrants; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Blade undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.

Press Contacts
For Media Relations
Lee Gold
press@blade.com

For Investor Relations
Mathew Schneider
investors@blade.com